Quest Diagnostics (NYSE:DGX) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $210.00 price target on the stock.
Quest Diagnostics (NYSE:DGX) was downgraded by analysts at
Wall Street Ze
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year [Yahoo! Finance]
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year
Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect